Letrozole Drug Description
Letrozole is a medication primarily Letrozol Zentiva Film 2.5mg drug description used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It belongs to a class of drugs known as aromatase inhibitors, which work by decreasing the amount of estrogen produced in the body. This reduction in estrogen levels can slow or stop the growth of certain types of breast tumors that require estrogen to grow.
Mechanism of Action
The letrozole drug description highlights its function as an aromatase inhibitor. Aromatase is an enzyme involved in the conversion of androgens into estrogens. By inhibiting this enzyme, letrozole effectively lowers estrogen levels, making it less likely for estrogen-dependent tumors to thrive.
Indications
Letrozole is primarily indicated for:
- Adjuvant treatment of early-stage breast cancer in postmenopausal women.
- Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Reduction of recurrence risk in women with hormone receptor-positive breast cancer.
Dosage and Administration
The standard dosage of letrozole is usually 2.5 mg taken orally once daily. It is crucial for patients to adhere to their prescribed regimen and consult their healthcare provider regarding any adjustments in dosage. Letrozole can be taken with or without food, but consistency in intake time can help maintain stable drug levels in the body.
Side Effects
- Hot flashes
- Joint pain or stiffness
- Fatigue
- Nausea
- Bone density loss
Patients should report severe or persistent side effects to their healthcare provider. Regular monitoring of bone health is recommended due to the potential risk of osteoporosis associated with long-term use of letrozole.
Contraindications and Precautions
Before starting treatment with letrozole, patients should inform their healthcare provider if they have a history of:
- Allergic reactions to letrozole or other medications.
- Liver disease.
- Bone health issues, including osteoporosis.
Letrozole is contraindicated in premenopausal women and those who are pregnant or breastfeeding, as it may harm the fetus or infant.
Conclusion
In summary, the letrozole drug description outlines a vital treatment option for postmenopausal women battling hormone receptor-positive breast cancer. Its mechanism of action, indications, dosage guidelines, and potential side effects are essential for healthcare providers and patients alike. As with any medication, close monitoring and communication between patient and provider are key to optimizing treatment outcomes while minimizing risks.